Literature DB >> 16054733

Cell mediated and antibody immune response to inactivated hepatitis A vaccine.

P Schmidtke1, P Habermehl, M Knuf, C U Meyer, R Sänger, F Zepp.   

Abstract

The humoral and cellular immune response to inactivated hepatitis A vaccine was investigated dynamically in a time elapse study over 1 year. Fourty-five healthy volunteers, seronegative for anti-HAV, were vaccinated with 1440 enzyme-linked immunosorbent assay units (EU) of formalin-inactivated hepatitis A virus following a 0--6-month schedule. Serum anti-HAV levels and HAV-specific proliferation of peripheral blood mononuclear cells were measured at several time points over a 26- and 28-week period after the first and second injection, respectively. Distinct B and T cell responses were determined within 14 days after primary vaccination. The booster vaccination-induced immediate peak levels for the humoral (anti-HAV GMC=5376mIU/ml) as well as the cellular (median Deltacpm=14173cpm) response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054733     DOI: 10.1016/j.vaccine.2005.06.022

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

Review 2.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

Review 3.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

4.  Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment.

Authors:  Adriana Weinberg; Sharon Huang; Terence Fenton; Julie Patterson-Bartlett; Philimon Gona; Jennifer S Read; Wayne M Dankner; Sharon Nachman
Journal:  J Acquir Immune Defic Syndr       Date:  2009-09-01       Impact factor: 3.731

5.  A retrospective pooled analysis assessing the effect of age on the immunogenicity of Havrix™ in healthy adults.

Authors:  Olivier Van Der Meeren; Priya Crasta; Marc de Ridder
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 6.  A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children.

Authors:  Sameer Rao; J S Mao; Salman Motlekar; Zhuang Fangcheng; Ganesh Kadhe
Journal:  Hum Vaccin Immunother       Date:  2016-12       Impact factor: 3.452

7.  Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.

Authors:  Christien Rondaan; Victoria Furer; Marloes W Heijstek; Nancy Agmon-Levin; Marc Bijl; Ferdinand C Breedveld; Raffaele D'Amelio; Maxime Dougados; Meliha C Kapetanovic; Jacob M van Laar; Annette Ladefoged de Thurah; Robert Landewé; Anna Molto; Ulf Müller-Ladner; Karen Schreiber; Leo Smolar; Jim Walker; Klaus Warnatz; Nico M Wulffraat; Sander van Assen; Ori Elkayam
Journal:  RMD Open       Date:  2019-09-09

8.  Is There A Correlation Between COVID-19 and Hepatitis A and Hepatitis E Serum Antibody Level?

Authors:  Alireza Abdollahi; Samaneh Salarvand; Vahid Mehrtash; Bita Jafarzadeh; Reza Ghalehtaki; Saeed Nateghi
Journal:  Iran J Pathol       Date:  2021-08-02

Review 9.  Increasing Burden of Hepatitis A in Adolescents and Adults and the Need for Long-Term Protection: A Review from the Indian Subcontinent.

Authors:  Ashish Agrawal; Sanjeev Singh; Shafi Kolhapure; Bernard Hoet; Vidya Arankalle; Monjori Mitra
Journal:  Infect Dis Ther       Date:  2019-11-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.